Other
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Royalty Pharma Cash Provided by (Used in) Investing Activity, Including Discontinued Operation increased by 43.6% to -$477.87M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 194.8%, from $503.92M to -$477.87M. Over 3 years (FY 2021 to FY 2025), Cash Provided by (Used in) Investing Activity, Including Discontinued Operation shows an upward trend with a -6.8% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2018
Last reportedQ1 2026May 6, 2026
How to read this metric
Reflects the overall net movement of cash into or out of the investment portfolio and capital assets.
Detailed definition
The total net cash flow from investing activities, aggregating both continuing and discontinued operations. It provides...
Peer comparison
Standard consolidated cash flow metric across all industries.
Metric ID:
other_net_cash_provided_by_used_in_investing_activitiesHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | -$845.50M | -$551.65M | $11.17M | -$30.18M | -$1.43B | -$558.53M | -$63.43M | -$450.66M | -$1.00B | -$86.65M | -$893.18M | -$1.19B | -$505.59M | $503.92M | -$311.98M | -$958.31M | -$847.80M | -$477.87M |
| QoQ Change | — | — | +34.8% | +102.0% | -370.3% | <-999% | +60.8% | +88.6% | -610.4% | -121.9% | +91.3% | -930.8% | -33.5% | +57.6% | +199.7% | -161.9% | -207.2% | +11.5% | +43.6% |
| YoY Change | — | — | — | — | — | -68.6% | <-999% | -110.2% | +68.4% | — | +84.5% | <-999% | -164.7% | +49.4% | +681.6% | +65.1% | +19.7% | -67.7% | -194.8% |
Range-$1.43B – $503.92M
Avg YoY Growth-465.2%
Median YoY Growth-67.7%
Current Streak2 quarters growth
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's cash provided by (used in) investing activity, including discontinued operation?
- Royalty Pharma (RPRX) reported cash provided by (used in) investing activity, including discontinued operation of -$477.87M in Q1 2026.
- How has Royalty Pharma's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
- Royalty Pharma's cash provided by (used in) investing activity, including discontinued operation decreased by 194.8% year-over-year, from $503.92M to -$477.87M.
- What is the long-term trend for Royalty Pharma's cash provided by (used in) investing activity, including discontinued operation?
- Over 3 years (2021 to 2025), Royalty Pharma's cash provided by (used in) investing activity, including discontinued operation has grown at a -6.8% compound annual growth rate (CAGR), from -$2.00B to -$1.61B.
- What does cash provided by (used in) investing activity, including discontinued operation mean?
- The total net cash flow from all investing activities, including both ongoing and discontinued operations.